ImmuPharma plc
IMM.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | £11,037 | £14,636 | £5,039 | £7,482 |
| - Cash | £397 | £397 | £237 | £237 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £10,640 | £14,239 | £4,802 | £7,245 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£29 | £0 | -£45 | £0 |
| % Margin | – | – | – | – |
| EBITDA | -£601 | -£601 | -£933 | -£933 |
| % Margin | – | – | – | – |
| Net Income | -£919 | -£919 | -£1,048 | -£1,048 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.003 |
| % Growth | 0% | 24% | 0% | – |
| Operating Cash Flow | -£503 | -£503 | -£446 | -£446 |
| Capital Expenditures | £0 | £0 | -£1 | -£1 |
| Free Cash Flow | -£503 | -£503 | -£447 | -£447 |